Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure. In considering outcomes for ...

Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.

The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Growth hormone receptor (GHR) signaling in bladder cancer is associated with advanced tumor stages and poor survival outcomes. High GHR expression in tumors up-regulates genes involved in drug ...

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common ...

The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

In patients with locally advanced muscle-invasive bladder cancer who have undergone radical cystectomy and chemotherapy, adjuvant radiotherapy improves survival outcomes compared to observation only.

ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

New research from the Daffodil Centre, a partnership between Cancer Council NSW and the University of Sydney, has revealed that while cancer survival ...

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...